New dupixent copycat drug tested in healthy volunteers
NCT ID NCT07502534
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial compares a new drug called IBI3027 to the approved medication Dupixent. It involves 180 healthy Chinese men who receive a single injection of either drug. The goal is to see if IBI3027 is absorbed and cleared from the body similarly to Dupixent, and to check for any safety issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI3027 (a monoclonal antibody injection)
- What this could lead to
- If successful, this could show that IBI3027 is a safe and equivalent alternative to Dupixent, potentially offering a more affordable treatment option for conditions like asthma or eczema.
- What could go wrong
- This is an early Phase 1 trial in healthy volunteers, not patients. It only tests bioequivalence and safety, not effectiveness. The results may not predict how the drug works in people with the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Qingdao University Affiliated Hospital
Qingdao, Shandong, Shandong Province, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults